NewAmsterdam Pharma Announces Equity Incentive Plan Grants Pursuant to Nasdaq Rule

NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. NAMS or "NewAmsterdam" or the "Company"), a prominent late-stage clinical biopharmaceutical entity, is focused on the advancement of novel oral, non-statin medications tailored for individuals grappling with cardiovascular diseases. NewAmsterdam has recently disclosed the issuance of inducement grants as a strategic move under the Nasdaq Listing Rule 5635(c)(4). These grants represent a pivotal effort to attract and retain top-tier talent essential for the company's progression through pivotal clinical trials and toward commercialization of their pioneering therapies.

Fostering Growth Through Strategic Inducement Grants

The inducement grants serve as a cornerstone in NewAmsterdam's agenda to cultivate an environment conducive to innovation and success. By leveraging these grants, the company seeks to empower and incentivize its key employees and key newcomers, aligning their interests with the long-term goals of the organization and its shareholders. Such grants not only reflect the company's dedication to fostering a culture of excellence but also signal to the market NewAmsterdam's commitment to executing its strategic initiatives effectively.

Advancing Cardiovascular Treatments

In the battle against cardiovascular disease, NewAmsterdam stands at the forefront with its trailblazing oral treatments. The company's research and development efforts are concentrated on addressing the substantial unmet medical needs that exist within the cardiovascular space. Their portfolio of oral, non-statin therapeutics is strategically designed to offer new avenues of care for patients who are inadequately served by existing treatments. The inducement grants signify an investment in the human capital that drives this innovation, which has the potential to revolutionize the standard of care and vastly improve patient outcomes.

biopharmaceutical, cardiovascular, inducement